One of every six human beings suffers from a neurological disorder, according to the World Health Organization. That’s 1 billion people afflicted with conditions ranging from migraines to epilepsy to Parkinson’s and more – an immense burden on individuals, families, and economies.
Finding new treatments for neurological diseases rank among the active areas of medical research. MPI Research is in the thick of those efforts, bringing a unique and robust set of skills to help Sponsors advance the most promising compounds.
MPI Research is the first contract research organization (CRO) to offer fully GLP-compliant abuse liability assays in both rodents and nonhuman primates, in accordance with worldwide regulatory guidelines. Additionally, MPI Research conducts preclinical screening in standard models, addressing pain, as well as other neurological disorders.
MPI Research provides expertise in both surgical and nonsurgical methods that model an array of neurological disorders. We can replicate biological conditions, define the impact of potential treatments using comprehensive analytical tools and expertise, and provide detailed analysis that meets the needs of Sponsors—and takes aim at these debilitating diseases.
- Cerebral hemorrhage
- Dural repair
- Spinal cord crush injury
- Peripheral nerve transection and repair
- Spinal implants
- Partial nerve ligation
- Chemically induced neural inflammation
- Epidural, intracisternal, and intrathecal delivery
- Stereotaxic delivery
- Lumbar, thoracic, and cervical spinal cord injections
Years combined experience
Studies performed in the past 2 years